$CLX

Clorox Recall Covers 6.3 Million Cleaners. The Stock Fell Just 1.3%

Clorox (CLX) recalled 6.3 million units of scented Mistolin and Lestoil cleaners in Puerto Rico and the U.S. Virgin Islands due to potential Pseudomonas aeruginosa contamination. The stock fell 1.3% to $93.06. No injuries have been reported, and the recall's financial impact is unclear. Clorox's fiscal 2026 sales declined 5% to $6.72 billion, with adjusted EPS dropping 28%.

Original reporting
Published Sep 5, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 6, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clorox Recall Covers 6.3 Million Cleaners. The Stock Fell Just 1.3% — source image
Decision brief

The 30-second read

$CLXBearishLow
01

Why it matters

The recall adds a liability risk but the company has not disclosed a charge; investors may monitor claim rates and any expansion of the recall.

02

Market read

The recall introduces a modest downside risk for CLX; broader market impact is limited.

03

What to watch

Potential insurance recoveries and the company's strong cash flow cushion.

Relevance 4/10Novelty 2/10Timing: post‑recall announcement

Background

Clorox announced a recall of scented Mistolin and Lestoil cleaners sold in Puerto Rico and the US Virgin Islands after regulator warning of possible Pseudomonas contamination.

Company-level read

Ticker impact

$CLXBearishMedium confidence
Context

Clorox (CLX) disclosed a 6.3 million‑unit cleaner recall and the stock fell 1.3% after the regulator announcement.

Expected impact

Modest further decline if additional products are added or claim rates rise.

Evidence & confidence

Recall is newly reported but the market has already priced most of the slide; risk remains limited without disclosed charge.

Market effects

Consumer products sector may see heightened scrutiny of product safety.

US territories (Puerto Rico, USVI) affected; limited broader regional effect.

Minimal global impact; primarily a US‑focused consumer‑goods issue.

Counterpoint

If claim rates stay low, the recall could be a short‑term overreaction.

Key entities

  • Clorox Company

    US consumer products maker (ticker CLX).

  • U.S. Consumer Product Safety Commission

    Agency issuing the recall notice.

Related articles

$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.